Hong Kong’s Securities and Futures Commission (SFC) has directed the stock exchange to suspend trading of US-based biotech firm Cloudbreak Pharma pending an investigation into its US$78 million initial public offering (IPO) last year.
“The SFC has serious concerns that Cloudbreak’s initial public…
The Hong Kong Securities and Futures Commission investigates whether Cloudbreak Pharma's IPO was manipulated to create an artificial demand impression, while its shares accumulate a drop of more than 90% since the listing.